1114559-11-3

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(4-Chloro-3-fluorophenyl)ethanamine is used as a pharmaceutical compound for its potential therapeutic applications. Given its stimulant and entactogenic effects, it may be explored for the treatment of conditions that could benefit from these properties, such as certain mood disorders or cognitive enhancement.
Used in Research and Development:
In the scientific community, (S)-1-(4-Chloro-3-fluorophenyl)ethanamine serves as a research chemical, aiding in the study of the central nervous system and the mechanisms of action of amphetamine-like substances. This helps in understanding their effects and potential applications in medicine.
Used as a Recreational Drug:

Upstream product

• 5527-95-7 4-chloro-3-fluorobenzaldehyde 
• 787633-86-7 2-[1-(4-Chloro-3-fluoro-phenyl)-ethyl]-isoindole-1,3-dione 
• 339001-14-8 1-(4-chloro-3-fluoro-phenyl)-ethanol 

Downstream Products

• 900504-92-9 N-[1-(4-chloro-5-fluoro-2-nitro-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 
• 1395072-61-3 (R)-N-(1-(4-chloro-3-fluorophenyl)ethyl)-2-(tetrahydro-2H-pyran-4-ylamino)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxamide 

Relevant academic research and scientific papers

CB1 RECEPTOR MODULATORS

Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.

Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction

The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.

Substituted 1,4-diazepines and uses thereof

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein: R1, R2, R9, R10, Ra, Rd and M are defined herein; X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; and R3 is —CO2Rd, —CO2M, —OH, —NHRd, —SO2Rd, —NHCONHRd, optionally-substituted amidino or optionally-substituted guanidino; or R3—X— is hydrogen or an electron pair; R4 is oxygen or —NR9R10; R5 is cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; and R6, R7 and R8 are independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or R6 and R7, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with Ra.